Protective  ||| S:0 E:11 ||| JJ
activity  ||| S:11 E:20 ||| NN
of  ||| S:20 E:23 ||| IN
guanosine  ||| S:23 E:33 ||| NN
in  ||| S:33 E:36 ||| IN
an  ||| S:36 E:39 ||| DT
in  ||| S:39 E:42 ||| IN
vitro  ||| S:42 E:48 ||| JJ
model  ||| S:48 E:54 ||| NN
of  ||| S:54 E:57 ||| IN
Parkinson ||| S:57 E:66 ||| NNP
's  ||| S:66 E:69 ||| POS
disease  ||| S:69 E:77 ||| NN
Parkinson ||| S:77 E:86 ||| NNP
's  ||| S:86 E:89 ||| POS
disease  ||| S:89 E:97 ||| NN
( ||| S:97 E:98 ||| -LRB-
PD ||| S:98 E:100 ||| NNP
)  ||| S:100 E:102 ||| -RRB-
is  ||| S:102 E:105 ||| VBZ
a  ||| S:105 E:107 ||| DT
pathological  ||| S:107 E:120 ||| JJ
condition  ||| S:120 E:130 ||| NN
characterized  ||| S:130 E:144 ||| VBN
by  ||| S:144 E:147 ||| IN
a  ||| S:147 E:149 ||| DT
progressive  ||| S:149 E:161 ||| JJ
neurodegeneration  ||| S:161 E:179 ||| NN
of  ||| S:179 E:182 ||| IN
dopaminergic  ||| S:182 E:195 ||| JJ
neurons  ||| S:195 E:203 ||| NN
with  ||| S:203 E:208 ||| IN
the  ||| S:208 E:212 ||| DT
consequent  ||| S:212 E:223 ||| JJ
reduction  ||| S:223 E:233 ||| NN
of  ||| S:233 E:236 ||| IN
dopamine  ||| S:236 E:245 ||| JJ
content  ||| S:245 E:253 ||| NN
in  ||| S:253 E:256 ||| IN
the  ||| S:256 E:260 ||| DT
substantia  ||| S:260 E:271 ||| JJ
nigra ||| S:271 E:276 ||| NN
.  ||| S:276 E:278 ||| .
The  ||| S:278 E:282 ||| DT
neurotoxin  ||| S:282 E:293 ||| JJ
6-hydroxydopamine  ||| S:293 E:311 ||| NNP
( ||| S:311 E:312 ||| -LRB-
6-OHDA ||| S:312 E:318 ||| NNP
)  ||| S:318 E:320 ||| -RRB-
is  ||| S:320 E:323 ||| VBZ
widely  ||| S:323 E:330 ||| RB
used  ||| S:330 E:335 ||| VBN
to  ||| S:335 E:338 ||| TO
mimic  ||| S:338 E:344 ||| VB
the  ||| S:344 E:348 ||| DT
neuropathology  ||| S:348 E:363 ||| NN
of  ||| S:363 E:366 ||| IN
PD  ||| S:366 E:369 ||| NNP
in  ||| S:369 E:372 ||| IN
both  ||| S:372 E:377 ||| DT
in  ||| S:377 E:380 ||| IN
vivo  ||| S:380 E:385 ||| NN
and  ||| S:385 E:389 ||| CC
in  ||| S:389 E:392 ||| IN
vitro  ||| S:392 E:398 ||| JJ
experimental  ||| S:398 E:411 ||| JJ
models ||| S:411 E:417 ||| NNS
.  ||| S:417 E:419 ||| .
We  ||| S:419 E:422 ||| PRP
found  ||| S:422 E:428 ||| VBD
that ||| S:428 E:432 ||| IN
,  ||| S:432 E:434 ||| ,
as  ||| S:434 E:437 ||| RB
expected ||| S:437 E:445 ||| VBN
,  ||| S:445 E:447 ||| ,
in  ||| S:447 E:450 ||| IN
dopaminergic  ||| S:450 E:463 ||| JJ
human  ||| S:463 E:469 ||| JJ
SH-SY5Y  ||| S:469 E:477 ||| CD
neuroblastoma  ||| S:477 E:491 ||| CD
cells  ||| S:491 E:497 ||| NNS
the  ||| S:497 E:501 ||| DT
toxin  ||| S:501 E:507 ||| NN
reduced  ||| S:507 E:515 ||| VBN
cell  ||| S:515 E:520 ||| NN
viability  ||| S:520 E:530 ||| NN
causing  ||| S:530 E:538 ||| VBG
programmed  ||| S:538 E:549 ||| JJ
cell  ||| S:549 E:554 ||| NN
death  ||| S:554 E:560 ||| NN
as  ||| S:560 E:563 ||| IN
assessed  ||| S:563 E:572 ||| VBN
by  ||| S:572 E:575 ||| IN
an  ||| S:575 E:578 ||| DT
increase  ||| S:578 E:587 ||| NN
in  ||| S:587 E:590 ||| IN
DNA  ||| S:590 E:594 ||| NNP
fragmentation ||| S:594 E:607 ||| NN
.  ||| S:607 E:609 ||| .
We  ||| S:609 E:612 ||| PRP
also  ||| S:612 E:617 ||| RB
examined ||| S:617 E:625 ||| VBN
,  ||| S:625 E:627 ||| ,
in  ||| S:627 E:630 ||| IN
these  ||| S:630 E:636 ||| DT
cells ||| S:636 E:641 ||| NNS
,  ||| S:641 E:643 ||| ,
the  ||| S:643 E:647 ||| DT
activation ||| S:647 E:657 ||| JJ
/ ||| S:657 E:658 ||| CD
inactivation  ||| S:658 E:671 ||| NN
of  ||| S:671 E:674 ||| IN
several  ||| S:674 E:682 ||| JJ
pro  ||| S:682 E:686 ||| NN
and  ||| S:686 E:690 ||| CC
anti  ||| S:690 E:695 ||| FW
apoptotic  ||| S:695 E:705 ||| FW
signaling  ||| S:705 E:715 ||| FW
pathways  ||| S:715 E:724 ||| FW
by  ||| S:724 E:727 ||| FW
6-OHDA  ||| S:727 E:734 ||| FW
including  ||| S:734 E:744 ||| FW
p-38  ||| S:744 E:749 ||| FW
kinase  ||| S:749 E:756 ||| FW
( ||| S:756 E:757 ||| -LRB-
p-38 ||| S:757 E:761 ||| NNP
) ||| S:761 E:762 ||| -RRB-
,  ||| S:762 E:764 ||| ,
c-Jun  ||| S:764 E:770 ||| JJ
N-terminal  ||| S:770 E:781 ||| JJ
kinase  ||| S:781 E:788 ||| NNS
( ||| S:788 E:789 ||| -LRB-
JNK ||| S:789 E:792 ||| NNP
) ||| S:792 E:793 ||| -RRB-
,  ||| S:793 E:795 ||| ,
protein  ||| S:795 E:803 ||| NN
kinase  ||| S:803 E:810 ||| VBD
B  ||| S:810 E:812 ||| NNP
( ||| S:812 E:813 ||| -LRB-
also  ||| S:813 E:818 ||| RB
known  ||| S:818 E:824 ||| VBN
as  ||| S:824 E:827 ||| IN
Akt ||| S:827 E:830 ||| NNP
) ||| S:830 E:831 ||| -RRB-
,  ||| S:831 E:833 ||| ,
glycogen  ||| S:833 E:842 ||| FW
synthase  ||| S:842 E:851 ||| FW
kinase-3β  ||| S:851 E:861 ||| FW
( ||| S:861 E:862 ||| -LRB-
GSK3β ||| S:862 E:867 ||| NNP
) ||| S:867 E:868 ||| -RRB-
,  ||| S:868 E:870 ||| ,
and  ||| S:870 E:874 ||| CC
Bcl-2  ||| S:874 E:880 ||| CD
protein ||| S:880 E:887 ||| NN
.  ||| S:887 E:889 ||| .
Guanine-based  ||| S:889 E:903 ||| JJ
purines ||| S:903 E:910 ||| NN
,  ||| S:910 E:912 ||| ,
exert  ||| S:912 E:918 ||| JJ
neuroprotective  ||| S:918 E:934 ||| JJ
effects  ||| S:934 E:942 ||| NNS
and  ||| S:942 E:946 ||| CC
we  ||| S:946 E:949 ||| PRP
previously  ||| S:949 E:960 ||| RB
reported  ||| S:960 E:969 ||| VBN
that  ||| S:969 E:974 ||| IN
guanosine  ||| S:974 E:984 ||| FW
activates  ||| S:984 E:994 ||| FW
cell  ||| S:994 E:999 ||| FW
survival  ||| S:999 E:1008 ||| FW
pathways  ||| S:1008 E:1017 ||| FW
including  ||| S:1017 E:1027 ||| FW
PI3K ||| S:1027 E:1031 ||| FW
/ ||| S:1031 E:1032 ||| FW
Akt ||| S:1032 E:1035 ||| FW
/ ||| S:1035 E:1036 ||| FW
PKB  ||| S:1036 E:1040 ||| FW
signaling  ||| S:1040 E:1050 ||| FW
in  ||| S:1050 E:1053 ||| IN
different  ||| S:1053 E:1063 ||| JJ
kinds  ||| S:1063 E:1069 ||| NNS
of  ||| S:1069 E:1072 ||| IN
cells  ||| S:1072 E:1078 ||| NNS
including  ||| S:1078 E:1088 ||| VBG
glia  ||| S:1088 E:1093 ||| NNS
and  ||| S:1093 E:1097 ||| CC
neuroblastoma  ||| S:1097 E:1111 ||| JJ
cells ||| S:1111 E:1116 ||| NNS
.  ||| S:1116 E:1118 ||| .
In  ||| S:1118 E:1121 ||| IN
the  ||| S:1121 E:1125 ||| DT
present  ||| S:1125 E:1133 ||| JJ
study  ||| S:1133 E:1139 ||| NN
we  ||| S:1139 E:1142 ||| PRP
found  ||| S:1142 E:1148 ||| VBD
that  ||| S:1148 E:1153 ||| DT
guanosine  ||| S:1153 E:1163 ||| NN
( ||| S:1163 E:1164 ||| -LRB-
300  ||| S:1164 E:1168 ||| CD
µM ||| S:1168 E:1170 ||| NN
)  ||| S:1170 E:1172 ||| -RRB-
protected  ||| S:1172 E:1182 ||| VBD
SH-SY5Y  ||| S:1182 E:1190 ||| CD
neuroblastoma  ||| S:1190 E:1204 ||| CD
cells  ||| S:1204 E:1210 ||| NNS
when  ||| S:1210 E:1215 ||| WRB
they  ||| S:1215 E:1220 ||| PRP
were  ||| S:1220 E:1225 ||| VBD
exposed  ||| S:1225 E:1233 ||| VBN
to  ||| S:1233 E:1236 ||| TO
6-OHDA ||| S:1236 E:1242 ||| CD
,  ||| S:1242 E:1244 ||| ,
promoting  ||| S:1244 E:1254 ||| VBG
their  ||| S:1254 E:1260 ||| PRP$
survival ||| S:1260 E:1268 ||| NN
.  ||| S:1268 E:1270 ||| .
Guanosine  ||| S:1270 E:1280 ||| NNP
reduced  ||| S:1280 E:1288 ||| VBD
the  ||| S:1288 E:1292 ||| DT
6-OHDA  ||| S:1292 E:1299 ||| JJ
mediated  ||| S:1299 E:1308 ||| JJ
activation  ||| S:1308 E:1319 ||| NN
of  ||| S:1319 E:1322 ||| IN
p-38  ||| S:1322 E:1327 ||| NNP
and  ||| S:1327 E:1331 ||| CC
JNK ||| S:1331 E:1334 ||| NNP
.  ||| S:1334 E:1336 ||| .
Moreover  ||| S:1336 E:1345 ||| RB
the  ||| S:1345 E:1349 ||| DT
nucleoside  ||| S:1349 E:1360 ||| NN
potentiated  ||| S:1360 E:1372 ||| VBD
the  ||| S:1372 E:1376 ||| DT
early  ||| S:1376 E:1382 ||| JJ
increase  ||| S:1382 E:1391 ||| NN
in  ||| S:1391 E:1394 ||| IN
the  ||| S:1394 E:1398 ||| DT
phosphorylation  ||| S:1398 E:1414 ||| NN
of  ||| S:1414 E:1417 ||| IN
the  ||| S:1417 E:1421 ||| DT
anti-apoptotic  ||| S:1421 E:1436 ||| JJ
kinase  ||| S:1436 E:1443 ||| JJ
Akt  ||| S:1443 E:1447 ||| NNP
and  ||| S:1447 E:1451 ||| CC
the  ||| S:1451 E:1455 ||| DT
increase  ||| S:1455 E:1464 ||| NN
in  ||| S:1464 E:1467 ||| IN
the  ||| S:1467 E:1471 ||| DT
expression  ||| S:1471 E:1482 ||| NN
of  ||| S:1482 E:1485 ||| IN
the  ||| S:1485 E:1489 ||| DT
anti-apoptotic  ||| S:1489 E:1504 ||| JJ
Bcl-2  ||| S:1504 E:1510 ||| CD
protein  ||| S:1510 E:1518 ||| NN
induced  ||| S:1518 E:1526 ||| NN
by  ||| S:1526 E:1529 ||| IN
6-OHDA ||| S:1529 E:1535 ||| CD
.  ||| S:1535 E:1537 ||| .
In  ||| S:1537 E:1540 ||| IN
summary  ||| S:1540 E:1548 ||| VBG
our  ||| S:1548 E:1552 ||| PRP$
results  ||| S:1552 E:1560 ||| NNS
show  ||| S:1560 E:1565 ||| VBP
that  ||| S:1565 E:1570 ||| IN
guanosine  ||| S:1570 E:1580 ||| JJ
results  ||| S:1580 E:1588 ||| NNS
to  ||| S:1588 E:1591 ||| TO
be  ||| S:1591 E:1594 ||| VB
neuroprotective  ||| S:1594 E:1610 ||| VBN
in  ||| S:1610 E:1613 ||| IN
a  ||| S:1613 E:1615 ||| DT
recognized  ||| S:1615 E:1626 ||| VBN
in  ||| S:1626 E:1629 ||| IN
vitro  ||| S:1629 E:1635 ||| JJ
model  ||| S:1635 E:1641 ||| NN
of  ||| S:1641 E:1644 ||| IN
PD  ||| S:1644 E:1647 ||| NNP
thus  ||| S:1647 E:1652 ||| RB
suggesting  ||| S:1652 E:1663 ||| VBG
that  ||| S:1663 E:1668 ||| IN
it  ||| S:1668 E:1671 ||| PRP
could  ||| S:1671 E:1677 ||| MD
represent  ||| S:1677 E:1687 ||| VB
a  ||| S:1687 E:1689 ||| DT
new  ||| S:1689 E:1693 ||| JJ
potential  ||| S:1693 E:1703 ||| JJ
pharmacological  ||| S:1703 E:1719 ||| JJ
tool  ||| S:1719 E:1724 ||| NN
to  ||| S:1724 E:1727 ||| TO
be  ||| S:1727 E:1730 ||| VB
studied  ||| S:1730 E:1738 ||| VBN
in  ||| S:1738 E:1741 ||| IN
the  ||| S:1741 E:1745 ||| DT
therapeutic  ||| S:1745 E:1757 ||| JJ
approach  ||| S:1757 E:1766 ||| NN
to  ||| S:1766 E:1769 ||| TO
PD ||| S:1769 E:1771 ||| NNP
.  ||| S:1771 E:1773 ||| .
